FindTrial
Sign In

PF-07304814

DRUG5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Pfizer

Conditions

COVID-19Covid19HealthyViral Disease

Phase 1

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
CompletedNCT04535167
PfizerViral Disease
Start: 2020-09-09End: 2021-06-07Updated: 2023-05-03
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
CompletedNCT04627532
PfizerHealthy
Start: 2020-10-23End: 2020-12-17Updated: 2021-01-06
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
CompletedNCT05050682
PfizerHealthy
Start: 2021-10-07End: 2021-12-10Updated: 2025-10-20

Phase 3

ACTIV-3: Therapeutics for Inpatients With COVID-19
CompletedNCT04501978
National Institute of Allergy and Infectious Diseases (NIAID)Covid19
Start: 2020-08-04End: 2023-07-14Updated: 2023-08-25
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
TerminatedNCT05780541
National Institute of Allergy and Infectious Diseases (NIAID)COVID-19
Start: 2021-09-15End: 2023-07-14Updated: 2024-02-09

Related Papers

Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
Clinical Microbiology and Infection2025-02-062 citations
P-1904. The Interaction of Serum Biomarkers and Lymphopenia on Pulmonary COVID-19 Illness Progression in Hospitalized Patients
Open Forum Infectious Diseases2025-01-29
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
The Journal of Infectious Diseases2023-11-094 citations
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
Open Forum Infectious Diseases2023-07-0710 citations
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
2022-08-0922 citations
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
2022-07-0896 citations
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
2022-06-07173 citations
RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19
JCI Insight2022-03-1727 citations
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Science Translational Medicine2022-01-25208 citations
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
2021-12-23173 citations
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
2021-12-2169 citations
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
New England Journal of Medicine2020-12-22456 citations